Ž. Zvirbule

发表

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.

H. Gómez, Z. Aziz, M. Arbushites, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

R. Greil, B. Melichar, G. Steger, 2013, The Lancet. Oncology.

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer

A. Oza, A. Gadducci, N. Colombo, 2016, International Journal of Gynecologic Cancer.

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

K. Dhaene, F. Bassermann, F. Lordick, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and Safety Results From a Phase II, Placebo‐Controlled Study of Onartuzumab Plus First‐Line Platinum‐Doublet Chemotherapy for Advanced Squamous Cell Non–Small‐Cell Lung Cancer

R. Govindan, F. Hirsch, D. Gandara, 2017, Clinical lung cancer.

Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.

N. Hanna, R. Kaiser, M. Ahn, 2013 .

Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer

H. Gómez, Z. Aziz, Yun Wu, 2010, Current medical research and opinion.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.

R. Greil, B. Melichar, G. Steger, 2016, The Lancet. Oncology.

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.

S. Loi, D. Miles, J. Sohn, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer

M. Burotto, E. Felip, E. Pozzi, 2021, Clinical pharmacology in drug development.

A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer

G. Hall, V. Ostapenko, B. Melichar, 2017, International Journal of Gynecologic Cancer.

Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial.

R. Greil, G. Steger, M. Inbar, 2010 .

Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).

Sung-Bae Kim, S. Loi, D. Miles, 2019, Journal of Clinical Oncology.

Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.

Melissa L. Johnson, C. H. van der Leest, B. Cho, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study

R. Govindan, S. Novello, S. Ramalingam, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma

F. Lordick, B. Melichar, Ö. Türeci, 2016 .

636PEFFICACY AND SAFETY OF MULTIPLE DOSES OF IMAB362 IN PATIENTS WITH ADVANCED GASTRO-ESOPHAGEAL CANCER: RESULTS OF A PHASE II STUDY.

Georg von Wichert, F. Lordick, Ö. Türeci, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

IMscin001 Part 2: A randomised phase III, open-label, multicentre study examining the pharmacokinetics (PK), efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous in previously treated locally advanced or metastatic non-small-cell lung cancer and PK comparison to other

M. Burotto, E. Felip, X. Liu, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I

S. Loi, F. Du, D. Miles, 2018 .

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.

K. Dhaene, F. Bassermann, F. Lordick, 2019 .

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

R. Greil, B. Melichar, G. Steger, 2015 .

Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adeno

F. Lordick, B. Melichar, Ö. Türeci, 2016 .

Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil.

G. Purkalne, Z. Zvirbule, E. Skuja, 2018, Molecular and clinical oncology.

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.

R. Greil, G. Steger, M. Inbar, 2012, European journal of cancer.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Efficacy and Safety of Onartuzumab in Combination With First‐Line Bevacizumab‐ or Pemetrexed‐Based Chemotherapy Regimens in Advanced Non‐Squamous Non–Small‐Cell Lung Cancer

H. Wakelee, S. Novello, F. D. De Braud, 2017, Clinical lung cancer.

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.

H. Gómez, Z. Aziz, M. Arbushites, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients

H. Gómez, Z. Aziz, M. Arbushites, 2007 .